setrusumab   Click here for help

GtoPdb Ligand ID: 9202

Synonyms: BPS 804 | BPS804 | UX-143 | UX143
Compound class: Antibody
Comment: Setrusumab (BPS-804) is a fully human investigational monoclonal antibody targeting sclerostin (SOST; which is a negative regulator of bone formation), that is intended to improve bone density.
Development of anti-sclerostin antibodies by Novartis is claimed in patent WO2009047356 [3], although we cannot definitively conclude that BPS-804 is claimed within that patent application.
The potential of sclerostin as a therapeutic target in bone diseases was reviewed by Lewiecki (2014) [4].
References
1. Bartosik M, Windels O, von Brackel FN, Amling M, Oheim R. (2026)
Romosozumab in postmenopausal women with classical Osteogenesis imperfecta.
Arch Osteoporos, 21 (1). [PMID:42470570]
2. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. (2006)
Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
J Bone Miner Res, 21 (11): 1738-49. [PMID:17002572]
3. Kneissel M, Halleux C, Hu S-I, Diefenbach-Streiber B, Prassler J. (2009)
Compositions and methods for use for antibodies against sclerostin.
Patent number: WO2009047356. Assignee: Novartis Ag. Priority date: 12/08/2007. Publication date: 16/04/2009.
4. Lewiecki EM. (2014)
Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.
Ther Adv Musculoskelet Dis, 6 (2): 48-57. [PMID:24688605]
5. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R et al.. (2009)
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
J Bone Miner Res, 24 (4): 578-88. [PMID:19049336]
6. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
J Biol Chem, 280 (20): 19883-7. [PMID:15778503]
7. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K et al.. (2010)
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
J Bone Miner Res, 25 (5): 948-59. [PMID:20200929]